Neurocognitive and functional assessment of patients with brain metastases - A pilot study
Neurocognitive and functional assessment of patients with brain metastases - A pilot study
复制标题
DOI：
10.1097/00000421-200306000-00014
复制
发表时间：
2003-06-01
影响因子：
2.6
通讯作者：
Mehta, MP
中科院分区：
文献类型：
--
作者：
Herman, MA;Tremont-Lukats, I;Mehta, MP
脑转移患者的预后通常较差。单独的生存率不一定是临床结果的良好衡量标准。还需要考虑神经认知功能的测量以及疾病和治疗对功能状态的影响。尽管这些参数已经在原发性脑肿瘤患者中进行了测量，但尚未在脑转移患者中进行彻底评估。简易精神状态检查对脑肿瘤患者神经认知领域受损的评估有限。它对轻度损伤不太敏感，不能避免重复给药所记忆的学习内容，并且没有非英语患者所需的经过验证的替代形式。为了确定使用更全面的神经认知测试电池的可行性，对 30 名脑转移患者的运动、语言、执行和日常功能进行了评估。测试组包括霍普金斯语言学习测试、受控口语联想测试、凹槽钉板测试、路径制作测试 A 和 B 以及巴塞尔指数。在这项研究中，患者完全依从，平均测试完成时间为 23±6 分钟。尽管功能状态良好，但大多数患者表现出记忆和精细运动领域受损。神经认知测试电池可以而且应该用于参加临床试验的脑转移患者。
The outcome of patients with brain metastases is generally poor. Survival alone is not necessarily a good measure of clinical outcome. Measures of neurocognitive function and the impact of the disease and treatments on functional status also need to be considered. Although these parameters have been measured in patients with primary brain tumors, they have not been as thoroughly evaluated in patients with brain metastases. The Mini-Mental State Examination provides limited assessment of neurocognitive domains impaired in brain tumor patients. It is less sensitive to mild impairment, does not avoid memorized learning from repeat administration, and does not have validated alternative forms necessary for non-English speaking patients. To determine the feasibility of using a more comprehensive neurocognitive test battery, motor, verbal, executive, and daily functions were assessed in 30 patients with brain metastases. The test battery included the Hopkins Verbal Learning Tests, Controlled Oral Word Association Test, Grooved Pegboard Test, Trailmaking Tests A and B, and the Barthel Index. In this study, there was complete patient compliance, with average test completion time of 23 6 minutes. Despite high functional status, most patients demonstrated impairment in memory and fine motor domains. Neurocognitive test batteries can and should be used in patients with brain metastases enrolled in clinical trials.